EP4373520A4 - Compositions et vaccins pour le traitement et/ou la prévention d'infections à variants de coronavirus et méthodes d'utilisation de ceux-ci - Google Patents

Compositions et vaccins pour le traitement et/ou la prévention d'infections à variants de coronavirus et méthodes d'utilisation de ceux-ci

Info

Publication number
EP4373520A4
EP4373520A4 EP22845545.7A EP22845545A EP4373520A4 EP 4373520 A4 EP4373520 A4 EP 4373520A4 EP 22845545 A EP22845545 A EP 22845545A EP 4373520 A4 EP4373520 A4 EP 4373520A4
Authority
EP
European Patent Office
Prior art keywords
vaccines
compositions
treating
methods
preventing coronavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22845545.7A
Other languages
German (de)
English (en)
Other versions
EP4373520A1 (fr
Inventor
Himanshu Brahmbhatt
Jennifer Macdiarmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EnGeneIC Molecular Delivery Pty Ltd
Original Assignee
EnGeneIC Molecular Delivery Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/480,073 external-priority patent/US12357687B2/en
Application filed by EnGeneIC Molecular Delivery Pty Ltd filed Critical EnGeneIC Molecular Delivery Pty Ltd
Publication of EP4373520A1 publication Critical patent/EP4373520A1/fr
Publication of EP4373520A4 publication Critical patent/EP4373520A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22845545.7A 2021-07-22 2022-07-21 Compositions et vaccins pour le traitement et/ou la prévention d'infections à variants de coronavirus et méthodes d'utilisation de ceux-ci Pending EP4373520A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163224838P 2021-07-22 2021-07-22
US17/480,073 US12357687B2 (en) 2020-03-24 2021-09-20 Compositions and vaccines for treating and/or preventing viral infections, and methods of using the same
PCT/IB2022/056759 WO2023002433A1 (fr) 2021-07-22 2022-07-21 Compositions et vaccins pour le traitement et/ou la prévention d'infections à variants de coronavirus et méthodes d'utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
EP4373520A1 EP4373520A1 (fr) 2024-05-29
EP4373520A4 true EP4373520A4 (fr) 2025-06-11

Family

ID=84979156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22845545.7A Pending EP4373520A4 (fr) 2021-07-22 2022-07-21 Compositions et vaccins pour le traitement et/ou la prévention d'infections à variants de coronavirus et méthodes d'utilisation de ceux-ci

Country Status (3)

Country Link
EP (1) EP4373520A4 (fr)
TW (1) TW202311282A (fr)
WO (1) WO2023002433A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201160A1 (fr) 2017-04-28 2018-11-01 Agrospheres, Inc. Compositions et procédés d'immobilisation d'enzyme
CA3073449A1 (fr) 2017-09-25 2019-03-28 Agrospheres, Inc. Compositions et procedes de production et d'administration evolutive de produits biologiques

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200054689A1 (en) * 2018-07-23 2020-02-20 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396822B2 (en) * 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
CN110951756B (zh) * 2020-02-23 2020-08-04 广州恩宝生物医药科技有限公司 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用
US10973908B1 (en) * 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN111662389A (zh) * 2020-06-05 2020-09-15 广州中医药大学(广州中医药研究院) 一种SARS-CoV-2的融合蛋白及其疫苗组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200054689A1 (en) * 2018-07-23 2020-02-20 Engeneic Molecular Delivery Pty Ltd Compositions comprising bacterially derived minicells and methods of using the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIACALONE M J ET AL: "Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 24, no. 33-34, 14 August 2006 (2006-08-14), pages 6009 - 6017, XP028011074, ISSN: 0264-410X, [retrieved on 20060814], DOI: 10.1016/J.VACCINE.2006.04.063 *
HOSSEINI SEYEDE ATEFE ET AL: "Potential SARS-CoV-2 vaccines: Concept, progress, and challenges", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 97, 29 March 2021 (2021-03-29), XP086706109, ISSN: 1567-5769, [retrieved on 20210329], DOI: 10.1016/J.INTIMP.2021.107622 *
See also references of WO2023002433A1 *

Also Published As

Publication number Publication date
EP4373520A1 (fr) 2024-05-29
TW202311282A (zh) 2023-03-16
WO2023002433A1 (fr) 2023-01-26

Similar Documents

Publication Publication Date Title
EP4415755A4 (fr) Compositions ciblant ace2 et méthodes de traitement de la covid-19
EP4157448A4 (fr) Méthodes et compositions de traitement d'infections virales à arn
EP4408412A4 (fr) Compositions et procédés de traitement de céphalées
EP4132967A4 (fr) Méthodes de prévention d'une infection par le sars-cov-2 et de traitement de la covid-19
EP4171606A4 (fr) Compositions et méthodes de traitement de la covid-19
EP4307898A4 (fr) Compositions et procédés de décontamination de surfaces
EP4373520A4 (fr) Compositions et vaccins pour le traitement et/ou la prévention d'infections à variants de coronavirus et méthodes d'utilisation de ceux-ci
EP4516305A4 (fr) Procédé et composition pour prévenir ou traiter la myopie
EP4340860A4 (fr) Compositions et méthodes de traitement de la neuropathie
EP4337174A4 (fr) Méthodes et compositions pour le traitement d'infections virales
EP4304596A4 (fr) Compositions et méthodes de traitement de la polycythémie
EP4114411A4 (fr) Compositions et méthodes pour le traitement du cancer du pancréas
EP4142691A4 (fr) Composition de clofazimine et procédé de traitement ou de prophylaxie d'infections virales
EP4121038A4 (fr) Compositions et méthodes pour le traitement d'une infection à coronavirus et d'un compromis respiratoire
EP4103177A4 (fr) Compositions et méthodes pour le traitement et/ou la prévention de maladies oculaires
EP4217001A4 (fr) Compositions et méthodes de prévention et de traitement de lésion cutanée radique
EP4125835A4 (fr) Méthodes et compositions pour le traitement ou la prévention d'une affection inflammatoire
EP4175627A4 (fr) Composition et procédé de traitement d'infections
EP4103192A4 (fr) Compositions et méthodes de traitement d'infections à coronavirus
EP4204550A4 (fr) Composition et méthodes de traitement ou de prophylaxie de coronavirus et de cancers
EP4009981C0 (fr) Méthode et compositions pour le traitement d'une infection à coronavirus
EP4313304A4 (fr) Compositions et méthodes d'inhibition et de traitement d'infections virales
EP4323063A4 (fr) Compositions et procédés utiles pour le traitement de la leucodystrophie h-abc
EP4395844A4 (fr) Compositions et méthodes destinées au traitement de fractures osseuses
EP4326757A4 (fr) Nouvelles compositions et nouvelles méthodes de traitement d'infections à coronavirus

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250513

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20250507BHEP

Ipc: A61K 31/53 20060101ALI20250507BHEP

Ipc: A61K 31/675 20060101ALI20250507BHEP

Ipc: A61K 31/427 20060101ALI20250507BHEP

Ipc: A61K 38/21 20060101ALI20250507BHEP

Ipc: A61K 31/519 20060101ALI20250507BHEP

Ipc: A61K 31/635 20060101ALI20250507BHEP

Ipc: A61K 31/4706 20060101ALI20250507BHEP

Ipc: A61K 39/39 20060101ALI20250507BHEP

Ipc: A61K 39/215 20060101AFI20250507BHEP